In 11,181 consecutive STEMI patients, the use of DES increased over time and there were significant differences in patients who received DES versus BMS Using complex statistical modeling to adjust for measured and unmeasured confounders, the study provides real world data that the use of DES in STEMI is associated with reduced TVR and improved long-term survival Overwhelming evidence supports the use of current-generation DES as first line for STEMI.
© 2016 Wiley Periodicals, Inc.